All posts tagged: news


By Shuki Greer, Esq.

The security camera footage has been watched thousands of times. Breaking in through a skylight in the ceiling, dropping a ladder down, and methodologically getting away with dozens of bags of finished product. The video clearly shows that this was a professional job carried out by serious criminals. The estimated value stolen was over $1M, meaning an estimated tax revenue loss for Oregon of about $230,000. The culprits remain at large, and they may never be found.

masked criminal

This isn’t the only incident either. A quick internet search highlights several other high-profile incidents, with varying degrees of professionalism, danger, and dollars lost. While each of these incidents have differences, they all share something in common. The legal industry is known for having large amounts of cash on hand, surplus product lying around, with varying amounts of security in place. The industry is susceptible to these kind of targeted robberies, a fact which is unlikely to change in the near future.

Why is this the case? The answer starts with the fact that cannabis remains illegal at the federal level. The government classifies cannabis as a Schedule 1 drug, meaning it is considered to have no medical benefit and a high potential for abuse. Because that is the case, financial institutions have been hesitant to open accounts and do business with MRBs (Marijuana Related Businesses), because they fear financial penalties, asset forfeiture, as well as civil and criminal repercussions.

Beyond the fact that the government considers MRBs to be illegal drug trafficking operations, several related details make banks hesitant. Bankruptcy courts are (almost) completely closed to MRBs. That means that if a company goes under, the bank has no recourse to get its money back. Section 280E of the tax code means that MRBs pay exorbitantly high taxes, making them significantly less profitable, solvent, and viable as account holders. The industry also still carries a stigma that makes some banks concerned about their other clients, who may close accounts upon learning that the banks have been doing business with MRBs.

It’s not all bad news, however. This issue has been talked about for years, and as the number of states with legal cannabis industries grows, banks have become more willing to get involved. The federal government hasn’t been silent either. The well-known Cole Memo, put out by the Obama administration, essentially stated that as long as businesses were operating legally under state law, they were a low priority for enforcement, as federal resources were better spent elsewhere. Subsequently, the FinCEN (Financial Crimes Enforcement Network, a bureau of the Treasury) announced that banks doing business with MRBs should follow the Cole memo’s guidelines to determine whether their customers were operating legally under state law.

When the Trump administration took over, AG Jeff Sessions rescinded the Cole memo, stating that prosecutors already have discretion as to how to use their limited resources, and there was no need to single out MRBs for special treatment. This suggested to some that the DOJ was going to start going after MRBs even if they were operating legally under state law. Thankfully, this didn’t happen, at least not on the large scale that some feared might happen. However, doubt and uncertainly remained for financial institutions, most of whom refused to bank the money from MRBs. Earlier this year, FinCEN announced that they still expected banks doing business with MRBs to be reporting suspicious activity using the Cole memo guidelines. In a backhanded way, this was an announcement that it was ok for financial institutions to do business with MRBs, and many have begun or continued to do so.

As long as cannabis remains illegal at the federal level, there will be fear and risk that comes along with doing business with MRBs. This means that many companies choose to keep large amounts of cash on hand, created the obvious incentives that thieves look for when picking a target. If we don’t want these incidents to continue, we need to redouble our efforts to push legalization so that the financial, security, and investment opportunities catch up to the rate of business growth. Two helpful and relevant bills are currently making their way through Congress, though neither seems likely to become enacted. The MORE Act, a comprehensive overhaul of the cannabis laws recently passed the House Judiciary Committee. However, the bill is yet to be brought to a full House vote, and the Senate is even less likely to bring the bill to the floor. Then there is the SAFE Banking Act, which passed the House 321-109 earlier this year, in a landmark bipartisan victory. But that bill seems to be dead in the House, as Mitch McConnell positions himself as opposed to any movement in the field. As such, the immediate future for the industry does not seem to hold significant change, and these problems will persist. While I certainly do not want to see more of these incidents, we likely have not seen the last one.

masked bank robbers
read more


Kudos @abbierosner for this moving piece in CBD Today, “SENIORS, CBD, AND THE LAWS OF ATTRACTION” The article reviews an evolving #CBD playing field, the fears, the market, and a few sprinkled quotes by Dr Laurie Vollen, @JamiePaz, and me!

Infused Beauty Cover Image
Seniors, CBD, and the laws of attraction article substance

To explore related information, click the keywords below:

read more

Extensive Cannabis Studies Underway Globally

Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents

In Summary:

As of 2016, upwards of 60 clinical trials relating to the use of medical cannabis were in progress. The scope of clinical trials included conditions such as anxiety, cocaine dependence, infantile spasms, schizophrenia, solid tumor, and many more. The status of cannabis as a Schedule I drug, under the Controlled Substance Act, limits researchers’ ability to freely collect data if they require support from NIH funding. While there are opportunities for researchers to study cannabis and its derivatives with the support of private funds, this typically risks an appearance of sacrificed scientific integrity and independence. Very few private entities would condone research which might shed an unfavorable light on their products. On the other hand, current NIH-funded research requires the use of the national supply of cannabis, a crop well-known to be very limited in quality. Increasingly, more states have been legalizing the medical and recreational use of cannabis in recent years, allowing scientists with more opportunities for private funding in which to shed more light on the vast medicinal benefits of cannabis. Animal models and human trials have pointed toward clinical applications of medical cannabis including anxiety, nausea, seizures, and inflammation, although the array of competing and synergistic compounds within the plant seem to continually open new doors to relief from a large array of illnesses.

View this review (yellow link) or download:

This paper is also stored here:    inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDExtensive Cannabis Studies Underway Globally
read more

Masters Degree in Medical Cannabis

Starting this fall, the University of Maryland will offer a masters degree in medical cannabis. The university’s School of Pharmacy developed the Medical Cannabis Science and Therapeutics Master of Science program to train medical students to treat medical marijuana patients and conduct research on cannabis. 

Benjamin Caplan, MDMasters Degree in Medical Cannabis
read more

USA Today Report: Cannabis Consumers Reduce Use of painkillers, prescription drugs, alcohol

“Among all surveyed consumers, 49% reported reducing their over-the-counter painkiller use since starting cannabis, and 52% reduced prescription drug use. Another 37% said they’ve reduced alcohol consumption since starting cannabis”

Benjamin Caplan, MDUSA Today Report: Cannabis Consumers Reduce Use of painkillers, prescription drugs, alcohol
read more

Forbes feature: Solo Sciences

A worthy look at the future of consumer empowerment in cannabis and beyond: Solo Sciences, inc

Check out for more!

Benjamin Caplan, MDForbes feature: Solo Sciences
read more

5 Benefits of Vaping Cannabis (vs smoking)

Within the inhalation method of consuming cannabis, there are many different ways one can inhale it.

The ancient way was almost always to smoke it. In the modern era of cannabis consumption, there are many more popular and advanced ways to consume either flower or concentrates:

  1. “Desktop” models that may use electricity for amplified power,
  2. Portable models that are more useful for inhalation-on-the-go,
  3. Cartridge-based “vape pens” to vaporize potent concentrates in a simple mechanism.

In short time, we will likely see adoption of (and a quickly massive rise in popularity of) aerosolization and nebulized cannabis consumption too!

Are the benefits of vaping strictly limited to cannabinoids? Certainly not.

Are the benefits of vaping even limited to terpenoids? Certainly not.

What else is there? Flavonoids.

And still more? Combinations of these that create entirely new results!

Benjamin Caplan, MD5 Benefits of Vaping Cannabis (vs smoking)
read more

Solo Sciences Press

A sneak peek at the latest news coming about solo sciences, inc!

Imagine a future of cannabis, where consumers have the control of purchase decisions, based on accurate information about the brand and products they may want, and tamper-proof, third-party verification that what we are buying is actually what the package says it is? (and then… consider that this concept applies to products beyond cannabis, from food to beauty products, toys, entertainment…)

“The world of cannabis is murky, unpredictable, and often not safe,” said Ashesh Shah, CEO and founder of solo sciences and a former CIA profiler. “As brands and governments are struggling to fight the illicit market, we created solo* to solve that problem by creating transparency into what cannabis providers are actually selling to consumers. solo* is designed to keep people out of the dark when it comes to what they’re consuming and putting into their bodies, so they feel secure and knowledgeable about the products they’re purchasing.”

for more information about solo*:





Benjamin Caplan, MDSolo Sciences Press
read more

CED YouTube Channel


We have recently created our YouTube channel to share CED Educational Videos! 

Please subscribe to the channel and “like” videos… to support patient education and future content creation! 

… Stay tuned for interviews, exposés, DIY videos, and more education!

Benjamin Caplan, MDCED YouTube Channel
read more

Medical cannabis doctors left to handle “backlash” from patients over lack of availability

Though UK doctors have been able to prescribe cannabis since November 2018, very few prescriptions have been issued, because most forms of medical cannabis have not been approved by the government.

In response to thousands of disappointed patients, the House of Commons Health and Social Care Committee called for immediate clinical trials focusing on the treatment of intractable childhood epilepsy. 

View this review (yellow link) or download:

This paper is also stored here:      inside the CED Foundation Archive

To explore related information, click the keywords below:

Benjamin Caplan, MDMedical cannabis doctors left to handle “backlash” from patients over lack of availability
read more